FDA updates warning for liver injury due to fezolinetant - Contemporary OB/GYN
FDA warns of rare, serious liver injuries from fezolinetant (Veozah), updating prescribing info to include monthly liver blood tests for 2 months after initiation, then at months 3, 6, and 9, and advising immediate discontinuation at signs of liver injury.
Reference News
FDA updates warning for liver injury due to fezolinetant - Contemporary OB/GYN
FDA warns of rare, serious liver injuries from fezolinetant (Veozah), updating prescribing info to include monthly liver blood tests for 2 months after initiation, then at months 3, 6, and 9, and advising immediate discontinuation at signs of liver injury.